Why the study?
Does visit-to-visit systolic blood pressure variability predict mortality and dialysis inception in patients with chronic kidney disease?
Does visit-to-visit systolic blood pressure variability predict mortality and dialysis inception in patients with chronic kidney disease?
Visit-to-visit systolic blood pressure variability is an independent predictor of all-cause mortality, but not dialysis inception, in elderly patients with chronic kidney disease.
Answers are grounded in this paper and cite their sources.
SBPV may aid mortality risk stratification in elderly CKD; leaves open whether variability is modifiable or causal.
BACKGROUND: We investigated the effects of visit-to-visit systolic blood pressure variability (SBPV) on both mortality and dialysis inception in a cohort of chronic kidney disease (CKD) patients not requiring dialysis therapy. Furthermore, we also explored the carry-over effect of visit-to-visit SBPV on mortality after dialysis initiation. METHODS: We conducted a longitudinal retrospective, observational, multi-centre study in three tertiary care nephrology outpatient clinics. All the ambulatory CKD patients admitted to the outpatient clinics from 1 January 2004 to 31 December 2005 were screened for study eligibility. We selected all consecutive patients older than 18 years of age with a mean estimated glomerular filtration rate of <60 mL/min/m(2), free from cardiovascular disease. SBPV was defined as the ratio of the SD to the mean SBP of five values recorded during a run-in phase of 4-5 months. Data on dialysis inception and mortality were recorded through 31 December 2010. RESULTS: Overall, we selected a cohort of 374 elderly (median age: 79 years) subjects. A total of 232 (62%) and 103 (29%) patients were male and had diabetes, respectively. A significant association between SBPV and the risk of death but not of CKD progression to dialysis was noted at univariate and after multivariable adjustments (hazard ratio for all-cause mortality per 1% increase in SBPV: 1.05; 95% confidence interval: 1.02-1.09; P = 0.001). Notably, no lethal event was recorded after dialysis initiation. CONCLUSIONS: Current findings suggest that SBPV may be of use for risk stratification in CKD patients.
No takes yet. Share an insight, caveat, or question.
Iorio et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: